NaviFUS Corp.

NT$17.60As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6872Healthcare

Country Taiwan

PE (Fwd) —

TSR 4Y CAGR (2.47%)

Div yield —

ROE (30.88%)

Medical Devices

Beta (5Y) —

PE TTM —

TSR TTM (18.89%)

Mkt cap NT$1.245B

ROIC (42.76%)

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

NT$18

4.04%

(79.19%)

Price above Reference Value

TTM

FYE 31 Dec TWD

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

27.25

RevenueNT$M

—

19.53

22.48

27.53

10.48

9.597

(18.72%)

—

Revenue growth%

—

15.13

22.46

(61.92)

(8.45)

15.13

—

37.47

Gross margin%

—

84.47

52.61

35.17

(26.61)

36.64

43.89

—

(611.46)

Operating margin%

—

(373.34)

(339.96)

(402.77)

(1523.35)

(100.00)

(388.06)

—

(550.74)

Net margin%

—

(325.68)

(292.38)

(345.53)

(1416.19)

(100.00)

(335.61)

—

P/E ratio (avg)x

—

EV/EBITx

—

(7.97)

FCF yield (avg)%

—

(5.68)

(5.42)

(7.41)

(7.46)

(0.79)

(6.55)

—

(361.87)

FCF margin%

—

(417.80)

(392.05)

(486.26)

(1324.56)

(100.00)

(452.03)

—

0.657

FCF / Net incomex

—

1.283

1.341

1.407

0.935

—

1.312

—

(42.76)

ROIC%

—

(27.88)

(27.23)

(34.33)

(43.51)

(2.46)

(31.10)

—

(30.88)

Return on equity%

—

(13.11)

(14.48)

(21.03)

(28.63)

(1.98)

(17.76)

—

(26.26)

Return on assets%

—

(12.13)

(13.40)

(17.40)

(23.34)

(1.69)

(15.40)

—

(2.13)

EPSNT$

—

(1.12)

(1.17)

(1.56)

(2.14)

(0.14)

—

EPS growth%

—

(4.49)

(33.50)

(37.69)

93.54

(33.50)

—

6.91

Bookvalue per shNT$

—

8.51

7.50

7.88

8.02

6.95

(1.95%)

—

(1.40)

FCF per shareNT$

—

(1.43)

(1.56)

(2.19)

(2.00)

(0.14)

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

70.75

Shares (diluted)M

—

56.99

56.37

61.11

69.27

◌69.27

6.72%

—

Buyback yield%

—

1.09

(8.40)

(13.35)

◌—

(8.40)

—

0.034

D/E ratiox

—

0.077

0.057

0.036

0.034

0.047

—

1.074

Enterprise valueNT$B

—

1.212

1.504

1.671

1.694

1.128

11.80%

—

LT debtNT$M

—

Peers (US$36.43M)

Cap (US$)

AViTA Corporation

40.82M

5.838x

Bioptik Technology…

37.57M

11.30x

S&S Healthcare Holding…

32.47M

—

Broncus Holding…

36.31M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(417.6)

(265.4)

Own earn%

—

Sh yield%

—

(8.40)

Owners

Insiders/Inst%

7.20

6.74

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

2/3

EPS growth years

0/3

Dividend streakyrs

Op margin range%

−1523–−340

$1 testx

—

Incr. ROIC%

—

NaviFUS Corp., a medical device company, develops and sells focused ultrasound (FUS) solutions for the unmet needs in neuromedicine in Taiwan. The company develops NaviFUS, a neuronavigator-guided transcranial FUS system that delivers focal energy into deep tissues in the brain, as well as is used in various clinical applications, such as drug delivery, neuromodulation, immuno-stimulation, and others.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$10.48M

(18.72%)

1.00×

Cost of revenue

NT$13.27M

63.57%

8.15×

Operating expenses

NT$156.9M

20.63%

3.27×

Asset mix

Trend

Other

70.48%

Cash and investments

29.52%

Reinvestment returns

No breakdown available